Treatment with Standard and Low Dose of Conjugated Equine Estrogen Differentially Modulates Estrogen Receptor Expression and Response to Angiotensin II in Mesenteric Venular Bed of Surgically Postmenopausal Hypertensive Rats

Priscila Xavier Araujo, Tiago Januário Costa, Cinthya Echem, Maria Aparecida de Oliveira, Rosangela Aparecida Santos-Eichler, Lucas Giglio Colli, Francesc Jiménez-Altayó, Elisabet Vila, Eliana Hiromi Akamine, Ana Paula Dantas, Graziela Scalianti Cervolo, and Maria Helena Catelli de Carvalho

Department of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, Brazil. (P.X.A., T.J.C., C.E., M.A.O., R.A.S.E., L.G.C., E.H.A., M.H.C.C.); Department of Physiological Sciences, State University of Londrina, Londrina, Brazil. (G.S.C.), Facultad de Medicina, Departamento de Farmacología, Terapéutica I Toxicología, Institut de Neurociències, Universitat Autònoma de Barcelona, Bellaterra, Spain. (F.J.-A., E.V.); Group of Atherosclerosis and Coronary disease, Institut Clinic del Torax, Institut d'Investigaciones Biomédiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain. (A.P.D.)

Received February 1, 2017; accepted April 21, 2017

ABSTRACT

Standard hormone therapy for menopausal women [conjugated equine estrogen (CEE) 0.625 mg] has been associated with increased risk of venous thrombosis. Regimens containing a lower CEE dose (0.30 mg) have been used clinically to decrease side effects of supraphysiologic doses of estrogen. In this study, we determined the effects of standard (SD) and low dose (LD) of CEE on venular function in ovariectomized (OVX) spontaneously hypertensive rats (SHR). Contractions by angiotensin-II (Ang-II) in perfused mesenteric venular bed were markedly increased in OVX (21.5 ± 1.3 mmHg) compared with Sham (14.7 ± 1.1 mmHg, P < 0.05). CEE-SD did not modify Ang-II responses in OVX, whereas CEE-LD restored Ang-II contraction to Sham levels. Endothelial nitric oxide synthase (eNOS) inhibition by L-NAME increased Ang-II contractions in Sham and CEE-LD and was without effect in venules of OVX SHR and CEE-SD. In OVX there was decreased NO generation in association with diminished eNOS phosphorylation and increased O2• generation in the venular wall. CEE-LD reverted the deleterious effects of ovarectomy. Although CEE-SD augmented eNOS phosphorylation in OVX, it was unable to increase NO levels, probably owing to its inability to reduce O2•. Distinct effects by CEE-SD and CEE-LD parallel the differential modulation of Ang-II and estrogen receptors. Compared with Sham, CEE-LD increases Ang II receptor type 2, whereas CEE-SD modified ERβ expression in the venous bed. Interestingly, both CEE doses increased G protein-coupled estrogen receptor in OVX. Our data suggest that estrogen dose is an important factor for venous function. Although CEE-LD reversed deleterious effects of OVX, CEE-SD showed null effects despite its ability to increase eNOS activity.

Introduction

For decades, postmenopausal women have been using hormone therapy (HT) worldwide for the relief of menopausal symptoms. The beneficial effects of HT in urogenital atrophy and the prevention of osteoporosis have been well documented by randomized clinical trials (Christiansen et al., 1980; Horsman et al., 1983; Lindsay et al., 1984; Lindsay, 1993; The Writing Group for the PEPI Trial, 1995). In Western countries, oral formulations of conjugated equine estrogen (CEE) represent the most commonly prescribed HT (Steinkellner et al., 2012). However, serious concerns have been raised over the effects of CEE on the cardiovascular health of menopausal women following the release of data from the Women’s Health Initiative (WHI) randomized trial (Rossouw et al., 2002) and the Million Women Study (Beral and Collaborators, 2003). Results from these studies prompted many women in the United States to discontinue HT with CEE, and in Europe to practically abandon its use, and to seek

ABBREVIATIONS: Ang-II, angiotensin II; ATR, angiotensin II receptor; AT1-R, angiotensin II receptor type 1; AT2-R, angiotensin II receptor type 2; CEE, conjugated equine estrogen; CEE-LD, low dose of conjugated equine estrogen; CEE-SD, standard dose of conjugated equine estrogen; DAF-2, 4,5-diamidinofluorescein diacetate; DHE, dihydroethidium; eNOS, endothelial nitric oxide synthase; ER, estrogen receptor; GPER, G protein-coupled estrogen receptor; HT, hormone therapy; L-NAME, NG-nitro-L-arginine-methyl ester; NOS, nitric oxide synthase; O2•, reactive oxygen species; SHR, spontaneously hypertensive rats.
safer alternatives for treatment of menopausal symptoms (Files et al., 2011; Steinkellner et al., 2012).

CEE comprises more than 10 different forms of estrogens derived from the urine of pregnant mares. The main components are estrone and equilin, with smaller amounts of 17α-estradiol, equilenin, 17α-dihydroequilin, 17β-dihydroequilin, 17α-dihydroequilin, and 17β-dihydroequilin, and a minimal level of 17β-estradiol (see Table 1). In addition to CEE, the mixture also contains traces of progestins, androgens, and substances of unknown activity/modes of action (Barton et al., 2007; Bhavnani et al., 2008). As such, the CEE mixture is not considered bioidentical to naturally occurring estrogens in women (i.e., 17β-estradiol, estrone, and estriol) and therefore may not provide comparable effects. In fact, studies have shown that CEE effects are markedly lower than 17β-estradiol depending on cell type or tissue studied (Bhavnani et al., 2008; Novensa et al., 2011).

Other concerns, beside the type of estrogens, have been raised as probable causes of cardiovascular risk by CEE, including its association with medroxyprogesterone, the administration route, duration of treatment, and the administration of supraphysiologic doses of estrogen. With time, the dosage of HT regimens in postmenopausal women has declined progressively, and in the past 10 years the use of lower dose of HT has grown in popularity. At present, the regimens containing 0.30 mg of CEE are considered low-dose HT (Grodstein et al., 2000; Peeyananjarassri and Baber, 2005). Although the effects of the lower doses of HT have been questioned (Gambacciani et al., 2008), clinical studies have shown beneficial effects comparable to the standard dose of HT with fewer side-effects for postmenopausal women (Peeyananjarassri and Baber, 2005). These studies showed the efficacy of low-dose HT to prevent osteoporosis (Gambacciani et al., 2001; Lindsay et al., 2002; Gambacciani et al., 2003b) and relief of other symptoms associated with menopause (Gambacciani et al., 2003a). However, information on the cardiovascular risk/benefits of low-dose HT is still meager and controversial (Hale and Shufelt, 2015), and there is even less data on the effects of low-dose HT in venules.

Studies using animal models have demonstrated that treatment with oral CEE improves arterial function (Ceravolo et al., 2013) and, therefore, may be beneficial to the cardiovascular system. However, transdermal estrogen (Speroff, 2010) and oral CEE (Peeyananjarassri and Baber, 2005) have also been associated with increased risk of venous thrombosis (Hu and Grodstein, 2002; Blondon et al., 2014; Smith et al., 2014), suggesting that CEE may display opposing effects in arteries and veins.

The link between estrogen use and venous thromboembolism was identified more than 20 years ago, and extensive literature describes this risk. It has been demonstrated that the risk of venous thromboembolism increases as estrogen dose increases. The most prescribed oral dose of CEE (0.625 mg) leads to supraphysiologic plasma levels of estrogen in both postmenopausal women (Sarrel et al., 1998) and animal models (Costa et al., 2015), which may increase estrogen-associated side effects and contribute to the prothrombotic effects associated with HT. For that reason, there is increasing interest in applying lower-doses of HT in postmenopausal women (Gambacciani et al., 2003a; Peeyananjarassri and Baber, 2005; Zang et al., 2010).

In vitro evidence has increased that angiotensin II (Ang-II) plays a key role in the formation of thrombosis (González Ordóñez et al., 2000; Mogielnicki et al., 2005). Although Ang-II has no direct effect on platelet aggregation, it significantly potentiates platelet-endothelial cell adhesion (Senchenkova et al., 2014); therefore, Ang-II-induced changes in venular responses may be indicative of higher risk of vein thrombosis. In this regard, we sought to determine the effects of estrogen withdrawal (by ovariectomy) and different doses of CEE regimen on mesenteric venular responses to Ang-II and the intrinsic mechanisms involved. We used ovariectomized hypertensive female rats as our established experimental model of surgical menopause resembling postmenopausal hypertension in women.

**Methods**

**Animals.** We used spontaneously hypertensive female rats (SHR) that we ovariectomized (OVX) as an experimental comorbidity model of post-menopause and hypertension in women (Dantas et al., 1999; Fortepiani et al., 2003), on the basis that estrogen deprivation by ovariectomy and post-menopause induces endothelial dysfunction (Pinto et al., 1997; Virdis et al., 2000) and increases blood pressure when compared with healthy and younger premenopausal women (Barton and Meyer, 2009). Twelve-week-old female SHR were obtained from breeding stock of the Institute of Biomedical Sciences of University of São Paulo (ICB-USP). The study was approved by the Ethical Committee for Animal Research of the Institute of Biomedical Sciences, University of São Paulo (Protocol number 145, page 95, book 2, December 06, 2010). Rats were ovariectomized as previously described (Dantas et al., 1999). Thirty days after ovariectomy, a group of OVX SHR was treated by gavage for 15 days with either a standard dose (SD) of CEE (CEE-SD; Premarin 9.6 μg/kg/day; Pfizer) or a low dose (LD) of CEE (CEE-LD; Premarin .96 μg/kg/day; Pfizer). To extrapolate standard and low doses of CEE from women to rats, we considered body mass index of postmenopausal women described in the Women’s Health Initiative (approximately 65 kg) and the standard dose of Premarin (0.625 mg/day) used to treat postmenopausal women (Rossouw et al., 2002). Age-matched female SHR in physiologic estrus were used as control (Sham). Physiologic estrus was determined by microscopic evaluation of vaginal smears, as described (Cora et al., 2015).

**Tissue Preparation for Immunofluorescence and Measurements of Reactive Oxygen Species and NO Production.** Segments of second- and third-order branches of the venular mesenteric bed were dissected free of fat and connective tissues and mounted in optimal cutting temperature (OCT) freezing medium. Cross-sections (10 μm) were obtained using a cryostat (Leica, Wetzlar, Germany).

**Blood Pressure Measurement.** Arterial blood pressure was determined in conscious rats by indirect tail-cuff plethysmography (pneumatic transducer, PowerLab 4/S; AD Instruments, Colorado Springs, CO), as previously described (Ceravolo et al., 2007). Systolic blood pressure was defined as the moment a definitive pulse could be detected. Results were calculated as an average of three consecutive measurements and expressed as millimeters of mercury.

**Effectiveness of Ovariectomy and Estrogen Therapy.** At the day of sacrifice, rats were anesthetized with sodium thiopental (50mg/kg, i.p.), a laparotomy was performed, and the uterus removed and dried for 24 hours in incubator at 37°C (dry weight). The results were expressed as milligrams of tissue and normalized by utis length (mg/cm). Peripheral blood was collected from abdominal aorta in a glass tube and centrifuged at 3000g, 15°C for 15 minutes to obtain the serum. Estrogen concentration was determined using the radioimmunoassay (Siemens Estradiol Coat-A-Count; Siemens Healthcare Diagnostics, Deerfield, IL) according to manufacturer’s protocol.
Mesenteric Venular Bed Perfusion. Isolated perfused mesenteric venular bed preparations were performed as previously described (Warner, 1990; Loiola et al., 2011). Rats were anesthetized with sodium thiopental (50 mg/kg, i.p.), the mesenteric bed was exposed, a cannula was inserted retrogradely into portal vein, and the vascular mesenteric bed was dissected out. The mesenteric venular bed was perfused using a peristaltic pump (Minipuls 3; Gilson, Middleton, WI) with Krebs-Henseleit solution at 37°C in the presence of 95% O2 and 5% CO2 for 40 minutes (the first 20 minutes at a constant rate of 2 ml/min and the remaining time at 4 ml/min).

After the equilibration period, 10 μM phenylephrine was perfused for 10 minutes to avoid desensitization of angiotensin II receptor type 1 (AT1R) followed by a bolus injection of angiotensin II (Ang-II) at 10 nM to 10 mM to produce contractile responses. Because significant effects of Ang-II were seen only at 10 μM, only results at this concentration were considered in this study. Ang-II responses were obtained in the absence or presence of L-NAME (NG-nitro-L-arginine-methyl ester, 100 μM), a nitric oxide synthase (NOS) inhibitor. Effects of NOS inhibition were calculated the change between basal (untreated) and stimulated (L-NAME) pressure perfusion (mm Hg).

Nitric Oxide Production. Basal NO production was measured using 4,5-diaminofluorescein diacetate (DAF-2), a fluorescent marker sensitive to NO. Sections (10 μm) were placed on glass slides and incubated at 37°C for 30 minutes with DAF-2 (12.5 μM) in phosphate buffer (0.01 M, pH 7.4) containing CaCl2 (0.45 mM). Digital images were captured in a microscope (Nikon E 1000; Melville, NY) equipped with epifluorescence. Mean optical density of fluorescence was analyzed by a computer system as previously described (Jiménez-Altayó et al., 2009). Immunofluorescence was performed with ImageJ (Wayne Rasband, National Institutes of Health) in three different locations of each image.

Reactive Oxygen Species Production. Reactive oxygen species (ROS) production was measured by dihydroethidium (DHE) fluorescence. The 10-μm sections were placed on glass slides and incubated at 37°C for 30 minutes in a light-protected and humidified chamber with DHE solution (5 μM). A ratio of excitation (260 nm) to the values obtained in Sham group.

Quantitative Real-Time Polymerase Chain Reaction. Total RNA (tRNA) was isolated from mesenteric venular bed using TRIzol Reagent (Thermo Fisher Scientific, Waltham, MA) per the manufacturer’s protocol. Total RNA quantification was done by spectrophotometry (260 nm) in NanoDrop (Thermo Fischer Scientific). Reverse transcription (RT) reaction was performed in a final volume of 20 μl using 2 μg tRNA mixed with 0.5 μg of oligo(dT) primer, 0.5 nM dNTP, 1× Moloney murine leukemia virus (MMLV) buffer, 10 mM dithiothreitol, 40 IU of RNase inhibitor, and 200 IU of MMLV enzyme. Samples were heated at 42°C for 50 minutes, 70°C for 15 minutes, and kept on ice. Real-time polymerase chain reaction (PCR) was performed in a final volume of 12.5 μl containing each oligonucleotide at 0.5 μM concentration (Table 2), and 50% of total volume of GoTaq qPCR Master Mix (Promega, Fitchburg, WI). Real-time PCR reactions were performed using a Corbett Research system (Corbett Life Sciences, Sydney, Australia). The conditions for PCR were as follows: 95°C for 2 minutes, 40 cycles of 95°C for 15 seconds, and 60°C for 1 minute. Expression data were calculated from cycle threshold (Ct) value using ΔΔCt method for quantification (Pfaffl, 2001). The β-actin mRNA was used for normalization and results were analyzed by fold increases relative to the values obtained in Sham group.

Immunofluorescence. Second-order branches of the superior mesenteric vein were fixed with 4% phosphate buffered paraformaldehyde (pH 7.4) for 1 hour and washed in three changes of phosphate buffered saline (pH 7.4). Frozen sections (20 μm) were incubated with a rabbit primary polyclonal antibody against ERα, ERβ, and G protein-coupled estrogen receptor (GPER) (1:50; Santa Cruz Biotechnology, Dallas, TX). After washing, sections were incubated with the secondary donkey anti-rabbit IgG antibody conjugated to Cy3 (1:200; Jackson Immunoresearch Laboratories Inc., West Grove, PA). Sections were processed for immunofluorescence staining essentially as previously described (Jiménez-Altabay, 2009). Immunofluorescent signals were viewed using an inverted Zeiss LSM 780-NLO confocal laser scanning microscope. Quantitative analysis of fluorescence was performed with ImageX (Wayne Rasband, National Institutes of Health). The average intensity was measured in at least two rings of each animal, and the results were expressed as arbitrary units.

Western Blotting. Frozen mesenteric venules were homogenized and protein extract obtained with lysis buffer containing 1% of Triton-X, 100 mM Tris pH 7.4, 100 mM sodium pyrophosphate, 100 mM sodium fluoride, 10 mM EDTA, 10 mM sodium orthovanadate, 2 mM phenylmethyl sulfonyl fluoride, and 0.01 mg/ml of protease inhibitor. Samples were centrifuged at 10,000g for 30 minutes at 4°C and protein content quantified by Pierce BCA Protein Assay Kit (cat no. 23227, Thermo Fisher Scientific), according to manufacturer’s protocol. An equal amount (70 μg) of total protein was separated by electrophoresis on a 10% polyacrylamide gel and transferred onto a nitrocellulose membrane. Non-specific binding sites were blocked with blocking solution (5% bovine serum albumin in TBS, pH 7.4). Western Blotting was done using an antibody (1:1000 dilution) against ERα, ERβ, G protein-coupled estrogen receptor (GPER) (ProteinTech, Chicago, IL), and β-actin (Santa Cruz Biotechnology, Dallas, TX) per the manufacturer’s protocol. The average intensity was measured in at least two rings of each animal, and the results were expressed as arbitrary units.

TABLE 1

<table>
<thead>
<tr>
<th>Constituents of conjugated equine estrogens</th>
<th>CER</th>
<th>Constituent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Estrogens</td>
<td></td>
<td>Estrone sulfate</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Equilin sulfate</td>
</tr>
<tr>
<td></td>
<td></td>
<td>17α-Dihydroequilinsulfate</td>
</tr>
<tr>
<td></td>
<td></td>
<td>17α-Estradiolsulfate</td>
</tr>
<tr>
<td></td>
<td></td>
<td>17β-Dihydroequilinsulfate</td>
</tr>
<tr>
<td></td>
<td></td>
<td>17α-Dihydroequilinsulfate</td>
</tr>
<tr>
<td></td>
<td></td>
<td>17β-Dihydroequilinsulfate</td>
</tr>
<tr>
<td></td>
<td></td>
<td>17β-Dehydroequilinsulfate</td>
</tr>
<tr>
<td></td>
<td></td>
<td>17β-Estradiolsulfate</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Δ8,9-Dehydroequilinsulfate</td>
</tr>
<tr>
<td>Progestins</td>
<td>5α-Pregnan-3,20-diol</td>
<td></td>
</tr>
<tr>
<td></td>
<td>5α-Pregnan-3,20-diol</td>
<td></td>
</tr>
<tr>
<td></td>
<td>5α-Pregnan-3,20-diol</td>
<td></td>
</tr>
<tr>
<td></td>
<td>5α-Pregnan-3,20-diol</td>
<td></td>
</tr>
<tr>
<td></td>
<td>5α-Pregnan-3,20-diol</td>
<td></td>
</tr>
<tr>
<td></td>
<td>3β-Hydroxy-5(10), 7-estriadiene-17-one-3-sulfate</td>
<td></td>
</tr>
<tr>
<td>Androgens</td>
<td>5α-Androstane-3β, 17β-diol</td>
<td></td>
</tr>
<tr>
<td></td>
<td>5α-Androstane-3β, 16α-diol</td>
<td></td>
</tr>
<tr>
<td></td>
<td>5α-Androstane-3β, 16α-diol</td>
<td></td>
</tr>
<tr>
<td></td>
<td>5α-Androstane-3β, 16α-diol</td>
<td></td>
</tr>
<tr>
<td></td>
<td>5α-Androstane-3β, 16α-diol</td>
<td></td>
</tr>
<tr>
<td>Other substances</td>
<td>5,7(9,10) Estratriene-3β, 17β-diol</td>
<td></td>
</tr>
<tr>
<td></td>
<td>17α-Dihydrodelta 8,9-dehydrostrogen</td>
<td></td>
</tr>
<tr>
<td></td>
<td>17β-Dihydrodelta 8,9-dehydrostrogen</td>
<td></td>
</tr>
<tr>
<td></td>
<td>17α-Dihydrostrogen</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2-Hydroxyestrenone</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2-Methoxyestrene</td>
<td></td>
</tr>
</tbody>
</table>

Barton et al. (2007); Bhavnani et al. (2008).

<table>
<thead>
<tr>
<th>TABLE 2</th>
<th>Oligonucleotides for real-time polymerase chain reaction</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gene</td>
<td>Sequence (5′ → 3′)</td>
</tr>
<tr>
<td>AT1R (NM_030985.4) F:</td>
<td>CACTTCTCTCGAGGCTAGC</td>
</tr>
<tr>
<td>AT2R (NM_007429.5) F:</td>
<td>CCGAGAAGACGCCTGAGAAG</td>
</tr>
<tr>
<td>eNOS (NM_021833.2) F:</td>
<td>TTCTGGCAGAAGCGGATACAGCAT</td>
</tr>
</tbody>
</table>

AT1R (NM_030985.4) R: | AGCAGATGTTTTCTGATTCAAGT |
| AT2R (NM_007429.5) R: | CTGGTGGTGGTGGTGGTGGTGGT |
| eNOS (NM_021833.2) R: | AAGGCGGAGAAGCCTTGGCA |

Downloaded from jpet.aspetjournals.org at ASPET Journals on November 17, 2022
7.4, containing 10 mM Tris-HCl, 100 mM NaCl, and 0.1% Tween 20] for 2 hours at room temperature. Membranes were incubated with specific antibodies overnight at 4°C. Primary antibodies were: mouse monoclonal anti-eNOS (1:1000, cat. no. 610297; BD Biosciences, San Jose, CA) and rabbit polyclonal anti-phospho-eNOSSer-1177 (1:1000, cat. no. 95715; Cell Signaling Technology, Danvers, MA). Membranes were incubated for 2 hours at room temperature with secondary antibodies: goat-anti-Mouse (1:10000, cat. no. 115-035-166; Jackson ImmunoResearch Laboratories Inc., West Grove, PA), and goat-anti-Rabbit (1:1500, cat. no. 111-035-144; Jackson ImmunoResearch Laboratories Inc.). Membranes were revealed with chemiluminescence (SuperSignal West Pico Chemiluminescent Substrate; Thermo Fisher Scientific), visualized by autoradiography film, quantified by densitometry using the ImageJ program (Wayne Rasband, National Institutes of Health). All membranes were reblotted using a monoclonal antibody anti-Actin (1:2000; Sigma-Aldrich) as a loading control. Data were normalized to corresponding values of α-Actin densitometry. Phosphorylation of endothelial nitric oxide synthase (eNOS) at Ser-1177 was expressed as the ratio of p-eNOSSer-1177 and total eNOS densitometry.

**Statistical Analysis.** Data are expressed as mean ± S.E.M. and n represents the number of animals used in each experiment. Differences between the groups were analyzed by one-way analysis of variance with Tukey-Kramer post-hoc test. Values of P < 0.05 were considered statistically significant.

**Results**

Systolic blood pressure was not modified by either ovariecomy or CEE treatments (Table 3). Uterine weight and serum levels of estrogen were reduced in OVX rats compared with Sham. Both CEE-SD and CEE-LD treatments restored the uterine weight to levels found in Sham. CEE-LD treatment increased estrogen to levels comparable with Sham, whereas the CEE-SD induced a 3.5-fold increase in serum estrogen levels (Table 3).

In venular bed, 10 μM Ang-II induced contractions in all groups (Fig. 1A). Contractile response to 10 μM Ang-II was higher in OVX compared with Sham. CEE-SD treatment did not modify Ang-II contraction compared with OVX. In contrast, the response induced by 10 μM Ang-II in CEE-LD was reduced compared with OVX, and similar to the response observed in Sham (Fig. 1B). In the presence of L-NAME, Ang-II contractions were markedly increased only in Sham and CEE-LD groups (Fig. 1C). L-NAME did not modify Ang-II responses in OVX and CEE-SD, suggesting an attenuation of NO release by Ang-II when estrogen is absent (OVX) or at supraphysiologic concentrations (CEE-SD). The increase in Ang-II responses in OVX was paralleled by a 2-fold increase in the ratio of AT1R/angiotensin II receptor type 2 (AT2R) (Fig. 2C) because of upregulation of AT1R (Fig. 2A) and unchanged AT2R expression (Fig. 2B). Treatment with CEE-SD restored the ratio of AT1R/AT2R to levels comparable to Sham, by decreasing AT1R expression. On the other hand, CEE-LD treatment led a 2-fold decrease AT1R/AT2R in OVX by restoring AT1R and inducing a 2-fold increase of AT2R.

To determine the intrinsic mechanisms that contribute to the altered Ang-II responses observed, we first determined NO production in venular sections by DAF-2 fluorescence. Our results reveal a diminished basal NO production in mesenteric venules by OVX SHR, compared with Sham (Fig. 3, A and B). Treatment of OVX SHR with CEE-SD did not modify venous production of NO compared with OVX; however, CEE-LD treatment increased this parameter to the values observed in Sham (Fig. 3, A and B). We next sought to determine whether a difference in the modulation of eNOS expression/activity could account for the disparity in NO production induced by SD and LD of CEE. We found that although the levels of eNOS protein and gene expression were similar in venules of all groups (Fig. 3C), the degree of eNOS phosphorylation at Serine-1177 was markedly reduced by OVX. Both CEE doses (SD and LD) equally increased eNOS phosphorylation in OVX females to the levels observed in Sham (Fig. 3C). Therefore, the inability of CEE-SD treatment to increase NO levels in venules of OVX SHR may not be dependent on changes of eNOS expression/activity; rather, it may be a consequence of increased NO degradation by O2.

In this regard, we next determined the effects of SD and LD of CEE on venular ROS generation. Measurements of ROS generation by DHE fluorescence showed an increase of oxidant stress in mesenteric venules by OVX compared with Sham (Fig. 4, A and B). Treatment with CEE-LD decreased DHE fluorescence in OVX to a degree similar to that observed in Sham. In contrast, CEE-SD did not modify DHE fluorescence in OVX (Fig. 4, A and B), suggesting dual dose-dependent effect of estrogen on ROS generation. Incubation of venular sections with polyethylene glycol–superoxide dismutase markedly decreased DHE signal in OVX and CEE-SD, revealing higher O2 levels in these groups. In the OVX group, DHE fluorescence was diminished by apocynin or losartan treatment, an indicative of the contribution of NADPH oxidase and AT1R in O2 generation, respectively (Fig. 4D). Interestingly in CEE-SD, ROS generation was also inhibited by L-NAME (Fig. 4E), suggesting O2 release by NOS when estrogen is at supraphysiologic levels. In Sham (Fig. 4C) and CEE-LD (Fig. 4F) all treatments were without effect on DHE signal.

We next explored the potential role of estrogen treatments on ERs expression that could correlate with the altered responses on NO/O2 production. Figure 5 we show the results of immunofluorescence analysis that determined the expression of estrogen receptors ERα, ERβ, and GPER along the venular wall of female SHR. In these studies, we observed that estrogen withdrawal by OVX was associated to an increased expression of ERβ and decreased expression of GPER. CEE-LD

**TABLE 3**

<table>
<thead>
<tr>
<th></th>
<th>Sham</th>
<th>OVX</th>
<th>CEE-SD</th>
<th>CEE-LD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Systemic blood pressure (mmHg)</td>
<td>171.3 ± 3.6</td>
<td>160.6 ± 3.3</td>
<td>170.3 ± 2.3</td>
<td>167.5 ± 1.8</td>
</tr>
<tr>
<td>Uterine weight (mg/cm)</td>
<td>2.65 ± 0.1</td>
<td>0.75 ± 0.1*</td>
<td>2.32 ± 0.1*</td>
<td>2.08 ± 0.2*</td>
</tr>
<tr>
<td>Estrogen (pg/ml)</td>
<td>30.1 ± 1.0</td>
<td>17.52 ± 1.2*</td>
<td>113.1 ± 13.3*</td>
<td>32.2 ± 6.9*</td>
</tr>
</tbody>
</table>

Statistical significance: P < 0.05 compared with Sham (*), OVX (#), or CEE-SD (+)
restored ERβ and GPER expression in OVX to levels observed in Sham. Although CEE-SD restored GPER, it further increased ERβ in venules of OVX SHR. No changes in ERα expression were observed.

Discussion

This is the first study describing the effects of standard and low dose estrogen treatment in venular function. The basis of our study was the evidence that standard dose of CEE has been associated with increased risk of venous thrombosis in menopausal women. Although regimens using lower doses of estrogen have been recommended to improve risk/benefits of

---

**Fig. 1.** Angiotensin II-induced contractions. Representative image of contraction by 10 μM Ang-II in mesenteric venular bed (A) and mean ± S.E.M. of maximal response obtained in venular bed of female SHR (B). The role of NO on Ang-II-induced contraction was assessed with L-NAME (100 μM) (C). Contractile responses were obtained in mesenteric venular bed from sham-operated (Sham), ovariectomized, and OVX rats treated with conjugated equine estrogens at standard and low dosages. Each point represents mean ± S.E.M. from six to eight independent experiment. *P < 0.05, **P < 0.01 by analysis of variance with Tukey-Kramer post-hoc test.

**Fig. 2.** Role of ovariectomy and CEE treatments on angiotensin II receptor expression. Bar graphs show the results of comparative analysis of mRNA levels of AT1R (A) and AT2R (B) in mesenteric venular bed from sham-operated (Sham), ovariectomized, and OVX rats treated with conjugated equine estrogens at standard and low dosages. mRNA levels are expressed as 2^−ΔΔCt using β-actin mRNA as internal control and Sham as reference group. (C) The ratios of AT1R/AT2R mRNA expression in each animal are expressed as Log 2. Data represent the mean ± S.E.M. derived from six independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001 by analysis of variance with Tukey-Kramer post-hoc test.
hormone therapy in the postmenopausal period (Santen, 2015), the dose-effect relationship in venous function was largely unknown. In this study, CEE-SD treatment in OVX led to supraphysiologic estradiol concentrations, whereas CEE-LD treatment resulted in similar serum estradiol concentrations than Sham. The different levels of circulating estrogens were associated with opposing effects of CEE-SD and CEE-LD on venular responses to Ang-II, and were in correlation with differential regulation of NO/O₂⁻ systems.

In the present study, we found that ovariectomy markedly increased Ang-II venular contractions, an effect that was improved by treatment with low doses of CEE but was not modified when CEE was administrated at standard doses. Inhibition of NOS by L-NAME led to an increase in Ang-II-induced contraction in the venular bed from Sham levels (∼32% increase in the maximal contraction) and CEE-LD levels (∼68%). On the other hand, L-NAME induced no changes in the contractile responses to Ang-II when estrogen levels were low (i.e., OVX) or at supraphysiologic levels (i.e., CEE-SD). These data clearly establish a difference in the contribution of NO attenuation of Ang-II contractile responses in the venular bed that prevails when estrogen is at physiologic concentration.

Two major cell surface G-protein-coupled receptor subtypes trigger vascular actions of Ang-II. Most of the detrimental effects of Ang-II are mediated by stimulation of AT₁R, whereas actions by AT₂R are known to compensate for vascular effects by AT₁R (Touyz and Schiffrin, 2000). We have previously demonstrated that estrogen modulates Ang-II receptor subtypes in the arterial bed of female SHR (Silva-Antonialli et al., 2004). Interestingly, we observed differences in the regulation of these receptors depending on the type of estrogen used and the serum estradiol concentration reached by each therapeutic regimen. When OVX SHR were treated with a regimen that led to a more physiologic concentration of estradiol (i.e., subcutaneous pellet of 50 μg 17β-estradiol), we observed a ratio of AT₁R/AT₂R in aortas and mesenteric arteries lower that in arteries from untreated OVX SHR (Silva-Antonialli et al., 2004). In opposition, when OVX SHR were treated with standard doses of CEE, reaching supraphysiologic levels of estradiol in the serum, we saw no differences in arterial expression of both AT₁R and AT₂R (Costa et al., 2015). In the present study, the greater venous constriction by Ang-II in OVX was paralleled by an increase in AT₁R expression. Treatment with low dose of CEE diminished AT₁R expression and concomitantly increased AT₂R in venules of OVX rats, an effect that was associated with a marked decrease in Ang-II contractions. Nevertheless, even though treatment with standard doses of CEE had decreased AT₁R expression in the mesenteric venular bed of OVX, we did not see any change in Ang-II-induced vasoconstriction, suggesting that treatment with CEE-SD modulates intrinsic molecular mechanisms that contribute to maintenance of Ang-II hypercontractility.

The favorable effects of estrogen on vascular function have been largely associated with regulation of NO production by mechanisms that involve genomic upregulation of the expression of the endothelial isoform of NOS (eNOS) (Goetz et al., 1994; Weiner et al., 1994). Nevertheless, most of the benefits of estrogen therapy on eNOS were described in the arterial bed (Chambliess and Shaul, 2002), although little is known about how estrogen therapies affect venular NO generation. In OVX SHR, we found an important disparity in the modulation of
venular NO bioavailability by standard and low doses of CEE. We observed that NO production and eNOS phosphorylation were decreased in OVX, and that low dose CEE restored this parameter. However, the standard dose of CEE did not modify NO bioavailability compared with OVX, despite its ability to promote eNOS phosphorylation. Therefore, we hypothesized that CEE-SD is ineffective in modifying NO availability in OVX, not because it lacks the ability to modulate NO release, but above all because it increases NO degradation after synthesis.

It is well established that the biologic activity of NO is modified by ROS such as $O_2^-$. Increased $O_2^-$ concentration in the vasculature results in rapid scavenging of NO and a decrease in its bioavailability (Touyz, 2003). In previous studies, we

![Figure 4](image-url)
have shown that CEE-SD treatment reduces ROS production in the arterial bed of OVX SHR by downregulating pro-oxidant and increasing antioxidant enzyme expression, which improves endothelial function (Ceravolo et al., 2013; Costa et al., 2015). Contrary to that, CEE-SD does not decrease O$_2^-$ generation in the venular bed of the same menopause model, revealing a differential regulation of NO/O$_2^-$ systems by estrogens in arteries and veins.

It has been shown that Ang-II increases O$_2^-$ production in different arterial beds via AT$_1$R-dependent and NADPH-oxidase–mediated signaling pathways (Griendling et al., 1994; Schramm et al., 2012). Angiotensin-II regulates the expression and activity subunit of NADPH (Nox) via AT1R in vivo. Infusion of Ang-II induced a significant increase in blood pressure, accompanied by augmented expression of Nox1 mRNA and O$_2^-$ production in aortas of Nox1 wild-type mice, whereas the elevation in blood pressure and production of O$_2^-$ were significantly blunted in Nox1 knockouts (Matsuno et al., 2005). In agreement with our previous studies of the mesenteric arterial bed (Dantas et al., 2002), our present data show that O$_2^-$ overproduction in mesenteric venules of OVX SHR is lessened by the blockage of AT$_1$R with losartan and by inhibition of NADPH-oxidase activity with apocynin. However, contrary to what was seen in the arterial bed (Ceravolo et al., 2013), treatment with CEE-SD did not decrease AT$_1$R and NADPH-derived O$_2^-$ production in venules and, moreover, facilitates O$_2^-$ generation via eNOS, as evidenced by decreased DHE fluorescence after L-NAME inhibition. Under normal conditions, the primary product of eNOS activation is NO, which produces beneficial effects on vascular biology. There is evidence, however, that in certain pathophysiological conditions when there is a depletion of important molecules essential for NO production (e.g., tetrahydrobiopterin, L-arginine) eNOS becomes increasingly “uncoupled” from NO production and produces O$_2^-$ (White et al., 2010). Although studies suggest that such conditions as aging and the presence of cardiovascular risk factors can modify the effects of estrogen on NO production owing to disarrangement of eNOS (White et al., 2010; Murphy, 2011), there is no data describing the direct effect of estrogen regimens and doses on eNOS uncoupling. Unfortunately, in our studies a few limitations (amount of tissue, assay sensitivity) did not allow us to better characterize the role of estrogens in eNOS uncoupling in veins. Nevertheless, our results on L-NAME inhibition of O$_2^-$ production bring new insight into the potential detrimental mechanisms of supraphysiologic doses of CEE.

Vascular estrogen actions are mediated by two members of the nuclear receptor superfamily (ER$_\alpha$ and ER$_\beta$) and by a GPER. ER$_\alpha$ has been described as the key player on cardiovascular protection by estrogen, although insufficient and controversial information is available on the contribution of ER$_\beta$ and GPER (Meyer and Barton, 2009). ER$_\alpha$ is known to...
upregulate eNOS expression (Sumi and Ignarro, 2003) and activates the enzyme via Ser-1177 phosphorylation (Tarhouni et al., 2013). However, recent evidence has recognized that GPER activation results in the rapid mobilization of intracellular calcium and activation of eNOS via Akt-mediated signaling pathway (Meyer et al., 2011). In our studies, we saw no changes in ERα expression in veins of OVX or CEE-treated rats. Instead, we found a major regulation of GPER expression by OVX and estrogen treatments. Our study is the first to describe that GPER expression in veins is decreased by estrogen withdrawal, and that chronic treatment with CEE restores GPER expression. Interestingly, changes in eNOS phosphorylation by OVX and CEE treatments were paralleled by variations in GPER expression in the venular wall.

Although this parallelism with GPER is a plausible explanation for the effects of CEE on eNOS phosphorylation, it does not correlate with the differences in NO bioavailability and O₂ production observed after treatment with low and standard doses of CEE. Interestingly, previous studies have shown that GPER can be associated with cardiovascular damage and increased O₂ production in aged females (Meyer et al., 2016). Moreover, in primary vascular smooth muscle cells from GPER knockout mice, the Ang-II-stimulating effect on O₂ production was completely absent (Meyer et al., 2016). In contrast, we found a marked difference in ERβ expression in the venular wall could better correlate with O₂ production. OVX induces an increase of ERβ expression that was corrected by CEE-LD, but not CEE-SD. In fact, the degree of ERβ expression after CEE-SD treatment was considerably higher by CEE-LD, but not CEE-SD. In fact, the degree of ERβ expression after CEE-SD treatment was considerably higher than the levels observed in OVX. The mechanisms to explain how the imbalance in ER ratio can modify estrogen effects are largely unknown, but recent studies have interestingly revealed that ERβ exhibits an inhibitory action on ERα-dependent gene expression and may oppose the actions of ERα (Matthews and Gustafsson, 2003; Bhavnani et al., 2008).

Taken together our data have established that CEE may display opposite effects in the venular function when administrated at standard or lower dose. Although treatment of OVX SHR with CEE-LD has a beneficial venular effect by increasing NO bioavailability and improving vascular responses to Ang-II, CEE-SD does not modify the detrimental induced by OVX. Although CEE-SD is as effective in activating eNOS to Ang-II, CEE-SD does not modify the detriment induced by decreasing NO bioavailability and improving vascular responses illustrated at standard or lower dose. Although treatment of OVX display opposite effects in the venular function when administrated at standard or lower dose.}

Acknowledgments

The authors are grateful to Marta Rodrigues and Sónia Maria Leite for technical support.

Authorship Contributions

Participated in research design: Araujo, Akamine, Vila, Dantas, Ceravolo, Carvalho.

Conducted experiments: Araujo, Costa, Echem, Oliveira, Santos-Echler, Colli, Jimenéz-Altayó.

Contributed new reagents or analytic tools: Araujo, Carvalho, Ceravolo, Dantas.

Performed data analysis: Araujo, Costa, Echem, Oliveira, Santos-Echler, Jimenéz-Altayó, Vila, Akamine, Dantas, Ceravolo, Carvalho.

Wrote or contributed to the writing of the manuscript: Araujo, Costa, Echem, Oliveira, Santos-Echler, Colli, Jimenéz-Altayó, Vila, Akamine, Dantas, Ceravolo, Carvalho.

References


